Switching from etelcalcetide to upacicalcet in maintenance hemodialysis patients-Reference-Cited by-同舟云学术

Switching from etelcalcetide to upacicalcet in maintenance hemodialysis patients

Published:2024 Issue:1 Volume:57 Page:5-14
ISSN:1340-3451
Container-title:Nihon Toseki Igakkai Zasshi
language:en
Short-container-title:Nihon Toseki Igakkai Zasshi

Author:

Yoshizawa Taku¹,Matsumoto Yohei²,Morita Rurino¹,Naito Yuko¹,Takahashi Naoko³

Affiliation:

1. Department of Pharmacy, Akane Foundation, Omachi Tsuchiya Clinic

2. Wellness Pharmacy Masuda-Nisseki-Byouin-mae-ten, Tsuruha Group Drug＆ Pharmacy Nishinihon, Inc.

3. Internal Medicine, Akane Foundation, Omachi Tsuchiya Clinic

Publisher

Japanese Society for Dialysis Therapy

Link

https://www.jstage.jst.go.jp/article/jsdt/57/1/57_5/_pdf

Reference20 articles.

1. 1) Kidney Disease：Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009；113：S1-130.

2. 2) Shigematsu T, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, Koshikawa S. Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism. Am J Nephrol 2009；29：230-6.

3. 3) Subramanian R, Zhu X, Kerr SJ, et al. Nonclinical pharmacokinetics disposition, and drug-drug interaction potential of a novel D-amino acid peptide agonist of the calcium sensing receptor AMG 416 (etelcalcetide). Drug Metab Dispos 2016；44：1319-31.

4. 4) 原田一恒，井上敦人，山内昭典，藤井章史．世界初の静注カルシミメティクス　エテルカルセチド塩酸塩（パーサビブ^Ⓡ静注透析用）の薬理学的特性と臨床効果．日薬理誌 2017；150：98-113．

5. 5) Block GA, Bushinsky DA, Cheng S. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism：a randomized clinical trial. JAMA 2017；317：156-64.